trending Market Intelligence /marketintelligence/en/news-insights/trending/6jd405fs1727rla-88zv7a2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Insmed files application with US FDA for lung disease therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Insmed files application with US FDA for lung disease therapy

Insmed Inc. a submitted a new drug application to the U.S. Food and Drug Administration for its lung disease treatment amikacin liposome inhalation suspension, or ALIS.

ALIS is aimed at treating adult patients with nontuberculous mycobacterial lung disease, a rare infection that can damage the lungs. The disease is caused by mycobacterium avium complex, a type of bacteria that affects people whose immune system is weak.

The application for the inhaled, once-daily formulation, is based on a successful phase 3 study, in which adding ALIS to standard treatment reduced bacterial density in 29% of the 336 adult patients enrolled.

Insmed expects to receive a six-month priority review from the U.S. FDA for ALIS.